Biota banks $20m, heads back to court
29 October, 2004 by Melissa TrudingerBiota (ASX: BTA) shareholders have shown resounding support for the company in an oversubscribed share purchase plan that has raised AUD$20 million.
License to grow says US CEO
29 October, 2004 by Melissa TrudingerIn-licensing of clinical-stage compounds for development is a useful way to build sustainable value for your company and fill out your pipeline, the CEO of San Diego company Structural Genomix (SGX) Timothy Harris told venture capitalists and other attendees at this week's AVCAL networking lunch in Melbourne.
NSW govt tipped to soften GM crop ban
28 October, 2004 by Graeme O'NeillIs the NSW Carr government -- the first state government to legislate for a moratorium on genetically modified crops -- having second thoughts?
Sirtex wins $1.3m Start grant
28 October, 2004 by Melissa TrudingerSirtex (ASX: SRX) has been awarded a AUD$1.311 million R&D Start grant from AusIndustry to commercialise its Targeted Hyperthermia Therapy.
Bush, Kerry both seen pressed to curb drug prices
27 October, 2004 by Staff WritersThe pharmaceutical industry is expected to face pressure to curb rising prescription-drug costs no matter which candidate wins next week's US presidential election.
NZ Roadshow: Why agbiotech must break free
27 October, 2004 by Graeme O'NeillIt's the Tasman paradox: although Australia and New Zealand are the world's leading exporters of grazing-derived products, they have both struggled to develop viable agricultural biotechnology industries. Why?
Peptech investee Domantis lands development deal
27 October, 2004 by Graeme O'NeillA potentially lucrative drug-development deal between UK pharma Argenta and domain-antibody pioneer Domantis limited has added a silver lining to the week for Sydney biotech Peptech (ASX:PTD), which has a 36.1 per cent stake in Domantis.
Novozymes looking for opportunities in Australia
26 October, 2004 by Melissa TrudingerDanish company Novozyme is aiming to become the "Intel" of biopharmaceuticals, and is looking for opportunities for partnerships, acquisitions and technology licensing in Australia.
GTG tests a hair of the dog
26 October, 2004 by Graeme O'NeillMelbourne's Genetic Technologies (ASX:GTX, NASDAQ:GNTLY) will be ensuring Australian punters won't be sold the proverbial pup, after signing an exclusive, five-year contract with Greyhounds Australasia to provide DNA-based parentage testing to the greyhound racing industry in Australia and New Zealand.
Pharmaxis' Aridol trial meets its endpoints
26 October, 2004 by Melissa TrudingerPharmaxis (ASX: PXS) has achieved a major milestone with the successful completion of the Phase III clinical trial for its asthma diagnostic and treatment management tool Aridol.
FDA clears PanBio's West Nile assay
26 October, 2004 by Renate KrellePanbio (ASX:PBO) has received US Food and Drug Administration clearance for its West Nile virus IgG diagnostic assay, and appointed former Woolworths and Elders IXL manager John Lee as a non-executive director and chairman of the company's board.
Peplin drug tests safe on the surface
26 October, 2004 by Graeme O'NeillBrisbane cancer-drug developer Peplin Biotech (ASX:PEP) is preparing to run a phase II trial of its promising skin-cancer drug PEP005 early next year, after completing a multi-centre, Phase I safety trial in US volunteers with actinic keratoses.
More haste less speed for Imugene bird flu vaccine, but project still alive
25 October, 2004 by Graeme O'NeillA development glitch may be responsible for the failure of a prototype vaccine against deadly avian influenza, developed by Sydney veterinary vaccine company Imugene (ASX:IMU).
Ventracor to beef up marketing and distribution
25 October, 2004 by Renate KrelleVentracor (ASX:VCR) has wrapped up a "successful" pilot trial of its VentrAssist artificial heart device -- including one bridge-to-transplant patient who has now received a donor heart -- and is set to beef up its marketing and distribution capabilities, shareholders heard today at the company's AGM.
Third-quarter results highlight big pharma's ills
25 October, 2004 by Ben HirschlerBig pharma looks sick. A host of third-quarter earnings figures this week confirms the mounting pressures faced by many drug makers on both sides of the Atlantic as prices are squeezed, sales growth in major markets slows and research productivity falls.
